Capital Network analyst Riccardo Lowi discusses Shield Therapeutics PLC’s (LON:STX) lead asset Feraccru - a novel and highly differentiated iron formulation, for oral administration, indicated for the treatment of iron deficiency. US regulators have set a target date for a decision on whether or not to approve it by 27 July 2019.
21 Jan 19